Over the last decade there has been a marked increase in the understanding the role of galectin-3 in myocardial fibrosis and inflammation and as a therapeutic target for the treatment of heart failure and myocardial infarction. The gene discussed is LGALS3; the disease is Myocardial fibrosis.